Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.

The factor VIII response to DDAVP (1-deamino-8-D-arginine vasopressin) was examined in 6 healthy volunteers. Following intravenous DDAVP infusion, each subject showed a marked increase in factor VIII procoagulant activity (VIII:C), factor VIII related antigen (VIIIR:AG) and von Willebrand factor activity (VIIIR:WF). But there were differences among augmentation index of each activity. Further investigations were performed whether there was a qualitative abnormality in the factor VIII after DDAVP infusion. Between factor VIII activities before and after DDAVP, there was no difference in a thermostability of VIII:C in vitro, gel chromatographic pattern on Sepharose 2B or 4B, a precipitation with concanavalin A (Con A) and a recovery in cryoprecipitate. The increase of VIIIR:AG, however, was mostly brought about by the augmentation of relatively slowly migrating portion as demonstrated by crossed immunoelectrophoresis (CIE). From these results it was assumed that there was no remarkable abnormalities in the factor VIII after DDAVP administration, and the elevated factor VIII could function efficiently in vivo. The findings in cryoprecipitation showed that DDAVP could be applied to blood donation for the preparation of cryoprecipitate.

[1]  A. Hellem.  Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method. , 2009, Scandinavian journal of haematology.

[2]  V. Marder,et al.  Effects of enzymatic degradation on the subunit composition and biologic properties of human factor VIII. , 1978, Blood.

[3]  I. Sussman,et al.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. , 1977, The Journal of clinical investigation.

[4]  P. Mannucci,et al.  1-DEAMINO-8-D-ARGININE VASOPRESSIN: A NEW PHARMACOLOGICAL APPROACH TO THE MANAGEMENT OF HAEMOPHILIA AND VON WILLEBRAND'S DISEASE , 1977, The Lancet.

[5]  P. Mannucci,et al.  Studies on the prolonged bleeding time in von Willebrand's disease. , 1976, The Journal of laboratory and clinical medicine.

[6]  R. Grant,et al.  A Method for Assaying von Willebrand Factor (Ristocetin Cofactor) , 1975, Thrombosis and Haemostasis.

[7]  P. Mannucci,et al.  Mechanism of Plasminogen Activator and Factor VIII Increase after Vasoactive Drugs , 1975, British journal of haematology.

[8]  J. Allain,et al.  Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. , 1975, The Journal of laboratory and clinical medicine.

[9]  H. Weiss,et al.  Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. , 1973, The Journal of clinical investigation.

[10]  C. Laurell,et al.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. , 1966, Analytical biochemistry.

[11]  K. Brinkhous,et al.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. , 1953, The Journal of laboratory and clinical medicine.

[12]  J. Sixma,et al.  Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. , 1978, The Journal of laboratory and clinical medicine.